Skip to main content
ZEISS Group Global
back
Global
Back to overview
Press Release

Carl Zeiss AG to increase its shareholding in Carl Zeiss Meditec AG by acquiring shares worth up to 200 million euros on the stock market

Carl Zeiss AG has decided to increase its current shareholding in Carl Zeiss Meditec AG through the acquisition of additional shares on the stock market.
22 June 2026
Page Content
Press contact
Oberkochen, Germany | June 22, 2026 | ZEISS Group

By acquiring the shares, Carl Zeiss AG underscores its clear commitment to Carl Zeiss Meditec AG and its strategic direction. As a major shareholder, Carl Zeiss AG stands firmly behind the company, demonstrating long-term support for Carl Zeiss Meditec AG and its continued growth through these additional share acquisitions.

Carl Zeiss AG stresses that, with the intended increase in its shareholding, it does not pursue any objectives beyond increasing its shareholding position. In particular, there are no plans to enter into a domination and profit transfer agreement or any other corporate agreement, nor to implement other structural measures, such as delisting or similar measures. With this acquisition of shares, Carl Zeiss AG pursues no plans to change the strategic direction of Carl Zeiss Meditec AG or its corporate structure.

Carl Zeiss AG continues to attach great importance to ensuring an adequate free float for Carl Zeiss Meditec AG. Carl Zeiss Meditec AG will also continue to have a broad shareholder base and ensure adequate tradability of its shares on the stock market. Against this backdrop, Carl Zeiss AG (including shares held indirectly through Carl Zeiss, Inc.) plans not to exceed 70% of the voting rights in Carl Zeiss Meditec AG.

The acquisition of shares is expected to be completed by the end of February 2027 and will be conducted exclusively on the stock market. The total volume of the planned purchases will not exceed 200 million euros. The timing and scope of the individual share acquisitions will be determined by prevailing market conditions. Carl Zeiss AG has commissioned an independent financial institution to purchase the shares. The commissioned financial institution makes its decisions independently and without influence from Carl Zeiss AG regarding the timing, scope, and price of the share acquisitions.

Press contact Jörg Nitschke

Head of Corporate Brand, Communications and Public Affairs
ZEISS Group

About ZEISS

ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling almost 12 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology, and Consumer Markets (September 30, 2025).

For its customers, ZEISS develops, produces, and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses, and binoculars.

With a portfolio aligned with future growth areas like digitalization, healthcare, and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 14 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.

With over 47,400 employees, ZEISS is active globally in around 50 countries with more than 60 sales and service locations, around 40 research and development facilities, and 30 production facilities worldwide (March 31, 2026). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.

Further information at www.zeiss.com

About Carl Zeiss Meditec AG

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the TecDAX and SDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,784 employees worldwide, the Group generated revenue of €2,228m in fiscal year 2024/25 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med
 

Disclaimer

This publication does not constitute a public offer to purchase shares of Carl Zeiss Meditec AG within the meaning of the German Securities Acquisition and Takeover Act or in any other respect. Nor is any public offer to purchase shares of Carl Zeiss Meditec AG being made or intended by Carl Zeiss AG or any person affiliated with it.

This publication does not create an obligation on the part of Carl Zeiss AG to acquire shares of Carl Zeiss Meditec AG, nor does it create an obligation on the part of the shareholders of Carl Zeiss Meditec AG to sell their shares. This publication also does not constitute a solicitation to the shareholders of Carl Zeiss Meditec AG to sell their shares.